Valeant Pharmaceuticals' ( VRX) shares rose 2.4% after it announced a partnership with Jazz Pharmaceuticals involving its Xyrem treatment for narcolepsy patients. The stock was adding 41 cents to $17.73 Friday. Under a license agreement, Valeant receives Canadian marketing rights to the drug for an upfront payment as well as payments based on future sales in Canada. Xyrem is the only product approved in Canada to treat cataplexy, the sudden loss of muscle tone associated with narcolepsy. Valeant expects to make the drug available to patients there in mid-2007 through its neurology sales force. "Xyrem is a strategic fit for our existing marketing and sales organizations in Canada," said Valeant's president and CEO Timothy Tyson in a press release Friday. "The product expands our neurology business in Canada in a niche market with unmet medical needs." "We are excited to be partnering with Valeant, which has a proven track record in commercializing pharmaceutical products, to bring this important treatment to patients in Canada," said Robert Myers, Jazz Pharmaceuticals' chief business officer.